Cormorant Asset Management
Boston, Massachusetts, United StatesFounded 2013
Cormorant Asset Management focuses on healthcare and life sciences, particularly biotechnology. They invest across both public and private markets, seeking innovative companies developing transformative therapies.
76% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 11 prior). Average disclosed round size is $117.5M (across 42 rounds with reported amounts).
Portfolio
42
Fund Size
$3.5B
Top Stage
Series B
Last 12 Mo
3
Team
RK
Raymond Kelleher
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
42 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 BlossomHill Therapeutics | Series B | $84M | Dec 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Electra Therapeutics | Series C | $183M | Oct 2025 |
 Attovia Therapeutics | Series C | $90M | Apr 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 Garuda Therapeutics | Series A | $50M | Mar 2025 |
 Umoja Biopharma | Series C | $100M | Jan 2025 |
 Numab Therapeutics AG | Series C | $55M | Jan 2025 |
 Axonis Therapeutics | Series A | $115M | Oct 2024 |
 Triveni Bio Inc. | Series B | $115M | Oct 2024 |
 Adona Medical | Series C | $33.5M | Jul 2024 |
| Attovia Therapeutics | Series B | $105M | May 2024 |
 Averto Medical Inc | Series A | $30.5M | May 2024 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
 Alumis Inc | Series C | $259M | Mar 2024 |
 Supira Medical, Inc. | Series D | $40M | Nov 2023 |
| Triveni Bio Inc. | Series A | $92M | Oct 2023 |
 Akura Medical | Series B | $35M | Oct 2023 |
| RRapport Therapeutics | Series B | $150M | Aug 2023 |
| BBioVentrix, Inc. | Series A | $48.5M | Apr 2023 |
 Chroma Medicine | Series B | $135M | Mar 2023 |
| CCARGO Therapeutics, Inc. | Series A | $200M | Mar 2023 |
 Tioga Cardiovascular | Series C | $30M | Feb 2023 |
| Adona Medical | Series B | $37.5M | Apr 2022 |
 Arkuda Therapeutics | Series B | $64M | Feb 2022 |
Page 1 of 2
Top Co-Investors
Janus Henderson Investors10 shared
OrbiMed7 shared
Logos Capital6 shared
Alexandria Venture Investments6 shared
Perceptive Advisors5 shared
RA Capital Management5 shared
HBM Healthcare Investment5 shared
Atlas Venture5 shared
Surveyor Capital5 shared
AMD Ventures5 shared
ARCH Venture Partners4 shared
DCVC4 shared
Redmile Group4 shared
Rock Springs Capital4 shared
venBio4 shared
Ally Bridge Group4 shared
The General Partnership4 shared
Deep Track Capital3 shared
Sanofi Ventures3 shared
Goldman Sachs Alternatives3 shared
Last updated: 16 April 2026